Urinary Tract Infections

Crucial research by Neil Osheroff and his lab leads to approval of the first new class of antibacterial drugs in decades. The drug, gepotidacin, developed by GlaxoSmithKline under the brand name Blujepa, will be available starting later this year, potentially bringing relief to thousands of women who struggle with uncomplicated urinary tract infections. Read More

Led by Neil Osheroff, Vanderbilt researchers are the first to undertake a systematic analysis of the mechanism of action of gepotidacin, a first-in-class triazaacenaphthylene antibacterial, against its targets in Escherichia coli—the type II topoisomerases gyrase and topoisomerase IV—and the mechanistic basis for drug resistance. E. coli is the etiological agent of most urinary tract infections. Read More